Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers
D Lane, I Matte, P Garde-Granger, C Laplante… - BMC cancer, 2015 - Springer
Background Platinum-based combination therapy is the standard first-line treatment for
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …
Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers
H Huang, Y Li, J Liu, M Zheng, Y Feng, K Hu… - PLoS …, 2012 - journals.plos.org
Objective The ability to predict responses to chemotherapy for serous epithelial ovarian
cancer (EOC) would be valuable since intrinsically chemoresistant EOC patients (persistent …
cancer (EOC) would be valuable since intrinsically chemoresistant EOC patients (persistent …
Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
D Lane, I Matte, C Rancourt, A Piché - BMC cancer, 2011 - Springer
Background The acellular fraction of epithelial ovarian cancer (EOC) ascites promotes de
novo resistance of tumor cells and thus supports the idea that tumor cells may survive in the …
novo resistance of tumor cells and thus supports the idea that tumor cells may survive in the …
[HTML][HTML] Profiling of cytokines in human epithelial ovarian cancer ascites
I Matte, D Lane, C Laplante, C Rancourt… - American journal of …, 2012 - ncbi.nlm.nih.gov
Background The behavior of tumor cells is influenced by the composition of the surrounding
tumor environment. The importance of ascites in ovarian cancer (OC) progression is being …
tumor environment. The importance of ascites in ovarian cancer (OC) progression is being …
Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in …
Objectives Epithelial ovarian cancer (EOC) typically presents with advanced disease. Even
with optimal debulking and response to adjuvant chemotherapy, the majority of patients will …
with optimal debulking and response to adjuvant chemotherapy, the majority of patients will …
[HTML][HTML] Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high …
I Matte, P Garde-Granger, P Bessette… - American Journal of …, 2019 - ncbi.nlm.nih.gov
About 20% of patients with high grade serous epithelial ovarian carcinoma (HGSOC) are
intrinsically resistant to standard first-line platinum-based combination therapy. There is no …
intrinsically resistant to standard first-line platinum-based combination therapy. There is no …
Molecular profiling and clinical outcome of high‐grade serous ovarian cancer presenting with low‐versus high‐volume ascites
T Feigenberg, B Clarke, C Virtanen… - BioMed research …, 2014 - Wiley Online Library
Epithelial ovarian cancer consists of multiple histotypes differing in etiology and clinical
course. The most prevalent histotype is high‐grade serous ovarian cancer (HGSOC), which …
course. The most prevalent histotype is high‐grade serous ovarian cancer (HGSOC), which …
[HTML][HTML] Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer
W Wei, N Li, Y Sun, B Li, L Xu, L Wu - Oncotarget, 2017 - ncbi.nlm.nih.gov
Some subsets of early stage ovarian cancer patients experience more recurrences than
others. Studies on prognostics factors gave conflicting results. We investigated consecutive …
others. Studies on prognostics factors gave conflicting results. We investigated consecutive …
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma
C Han, S Bellone, ER Siegel, G Altwerger… - Gynecologic …, 2018 - Elsevier
Introduction Since the majority of patients are diagnosed at an advanced stage, ovarian
cancer remains the most lethal gynecologic malignancy. There is no single biomarker with …
cancer remains the most lethal gynecologic malignancy. There is no single biomarker with …
Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients
V Dalal, R Kumar, S Kumar, A Sharma, L Kumar… - Clinica chimica acta, 2018 - Elsevier
Background Ovarian cancer is represented with significantly higher mortality rate
predominately due to asymptomatic behaviour during initial disease course and at diagnosis …
predominately due to asymptomatic behaviour during initial disease course and at diagnosis …